Ewing’s sarcoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:13:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ewing’s sarcoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma https://clinicaltrials.eu/trial/study-on-chemotherapy-with-gemcitabine-lenvatinib-and-temozolomide-for-patients-with-recurrent-and-primary-refractory-ewing-sarcoma/ Wed, 29 Apr 2026 15:02:19 +0000 https://clinicaltrials.eu/trial/study-on-chemotherapy-with-gemcitabine-lenvatinib-and-temozolomide-for-patients-with-recurrent-and-primary-refractory-ewing-sarcoma/ This clinical trial focuses on treating patients with Ewing Sarcoma that has either come back after treatment or did not respond to initial treatment. The study tests several chemotherapy medications including gemcitabine, docetaxel, irinotecan, temozolomide, topotecan, carboplatin, cyclophosphamide, ifosfamide, etoposide, and lenvatinib. The purpose is to determine which treatment combination works best in terms of effectiveness and side effects.

The treatment involves different combinations of these medications given either through an intravenous infusion into a vein or as oral capsules taken by mouth. Some medications are given daily while others are administered on specific days during treatment cycles that typically last several weeks. The total treatment duration may continue for up to 104 weeks depending on how well the treatment works.

Throughout the study, doctors will monitor the size of tumors using imaging scans to check if the treatment is working. They will also track any side effects and how long patients stay in the hospital. The study measures how long patients live without their disease getting worse and their overall survival time. Additionally, patients’ quality of life will be evaluated during the treatment period.

]]> Study on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-resistant-primary-bone-tumors/ Wed, 29 Apr 2026 15:00:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-resistant-primary-bone-tumors/ This clinical trial is focused on studying the effects of a medication called Regorafenib on patients with a type of cancer known as refractory primary bone tumors. These tumors are a form of cancer that originates in the bones and have not responded to previous treatments. The purpose of the study is to evaluate how effective and safe Regorafenib is for these patients.

Participants in the study will take Regorafenib in the form of a film-coated tablet, which is taken orally. The study will monitor patients over a period to see how the medication affects their condition. This includes observing any changes in the tumor, as well as any side effects that may occur. The study aims to determine if Regorafenib can help control the disease and improve the quality of life for patients.

Throughout the study, various health checks will be conducted, such as laboratory tests and heart monitoring, to ensure the safety of the participants. The study will also look at how the body processes the medication, including how long it takes to reach a steady level in the bloodstream. This information will help researchers understand the best way to use Regorafenib in treating refractory primary bone tumors.

]]>